Literature DB >> 10885824

The prevention of antibiotic resistance during treatment.

J D Williams1, A M Sefton.   

Abstract

Prevention of emergence of antibiotic resistance during treatment is an important goal when prescribing antimicrobials. Antibiotic resistant bacteria can emerge in three main ways--by acquisition of new genes via transposons or horizontal gene transfer, by selection of resistant variants and by selection of naturally resistant strains. In order to minimize emergence of antibiotic resistance during therapy it is important to try and avoid antibiotics which encourage the transfer of resistance genes, to avoid selection of resistant variants from susceptible pathogens and to avoid ablation of antibiotic susceptible normal flora. However, implementing these objectives is not always easy. This paper discusses possible ways of limiting the emergence of resistant bacteria during treatment. It does not consider how to prevent the spread of these strains from person to person. The prevalence of antibiotic-resistant bacteria depends upon the selection of antibiotic-resistant strains and spread of these strains from person to person. Prevention therefore consists of two parts--the prevention of acquisition of resistance/selection of antibiotic-resistant variants and interrupting the mechanisms by which person-to-person spread can occur. This paper considers only the first of these two influences on prevalence of resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10885824     DOI: 10.1007/BF02561667

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  Adaptive mutations produce resistance to ciprofloxacin.

Authors:  C Riesenfeld; M Everett; L J Piddock; B G Hall
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

2.  In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.

Authors:  M A Cohen; M D Huband; J W Gage; S L Yoder; G E Roland; S J Gracheck
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

3.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

Authors:  G J Duckworth; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

4.  Selection of resistant variants of respiratory pathogens by quinolones.

Authors:  A M Sefton; J P Maskell; J D Williams
Journal:  Int J Antimicrob Agents       Date:  1999-07       Impact factor: 5.283

5.  Levofloxacin selects fluoroquinolone-resistant methicillin-resistant Staphylococcus aureus less frequently than ciprofloxacin.

Authors:  M E Evans; W B Titlow
Journal:  J Antimicrob Chemother       Date:  1998-02       Impact factor: 5.790

  5 in total
  4 in total

Review 1.  Combination therapy as a tool to prevent emergence of bacterial resistance.

Authors:  J W Mouton
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 2.  Unraveling the Nature of Antibiotics: Is It a Cure or a New Hurdle to the Patient Treatment?

Authors:  Sai Sreeya Gude; Shravya Venu Gopal; Harshita Marasandra Ramesh; Sravya Vuppalapati; Nikhil Chowdary Peddi; Sai Sravya Gude
Journal:  Cureus       Date:  2022-04-08

3.  In vitro antimicrobial activity of ten medicinal plants against clinical isolates of oral cancer cases.

Authors:  Manju Panghal; Vivek Kaushal; Jaya P Yadav
Journal:  Ann Clin Microbiol Antimicrob       Date:  2011-05-20       Impact factor: 3.944

Review 4.  Can we prevent antimicrobial resistance by using antimicrobials better?

Authors:  Germander Soothill; Yanmin Hu; Anthony Coates
Journal:  Pathogens       Date:  2013-06-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.